Laboratory testing in the rheumatic diseases: A practical review

Southern Medical Journal

Volumn 98, Issue 2, 2005, Pages 185-191

  Colglazier, Christopher Lee ^a   Sutej, Paul George ^a   Morris, Christopher ^a,b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; DNA ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; LA ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; RHEUMATOID FACTOR; RO ANTIBODY; SINGLE STRANDED DEOXYRIBONUCLEIC ACID ANTIBODY; UNCLASSIFIED DRUG;

ANAMNESIS; DERMATOMYOSITIS; EARLY DIAGNOSIS; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; LABORATORY DIAGNOSIS; MEDICAL EXAMINATION; POLYMYOSITIS; RAYNAUD PHENOMENON; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SCLERODERMA; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES; ANTIBODIES, ANTINUCLEAR; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; PREDICTIVE VALUE OF TESTS; RHEUMATIC DISEASES; RHEUMATOID FACTOR;

EID: 14044268136     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.SMJ.0000153572.22346.E9     Document Type: Review

References (21)

1. Sox HC Jr, Liang MH. The erythrocyte sedimentation rate: guidelines for rational use. Ann Intern Med 1986;104:515-523.
2. Jones SA, Novick D, Horiuchi S, et al. C-reactive protein: a physiologic activator of interleukin 6 receptor shedding. J Exp Med 1999;189:599-604.
3. Zouki C, Beauchamp M, Baron C, et al. Prevention of in vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. J Clin Invest 1997;100:522-529.
4. Wener MH, Daum PR, McQuillan GM. The influence of age, sex, and race on the upper reference limit of serum C-reactive protein concentration. J Rheumatol 2000;27:2351-2359.
5. Morley JJ, Kushner I, et al. Serum C-reactive protein levels in disease. Ann N Y Acad Sci 1982;389:406-418.
6. Amos RS, Crockson RA, Crockson AP, et al. Rheumatoid arthritis: C-reactive protein and erythrocyte sedimentation rate during initial treatment. BMJ 1978;1:1396.
7. Solomon DH, Kavanaugh AJ, Schur PH, et al. Evidenced-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 2002;47:434-444.
8. Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 1997;40:1601-1611.
9. Kavanaugh AF, Solomon DH. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. Arthritis Rheum 2002;47:546-555.
10. Schur PH, Sandson J. Immunologic factors and clinical activity in systemic lupus erythematosus. N Engl J Med 1968;278:533-538.
11. Ter Borg EJ, Horst G, Hummel EJ, et al. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. Arthritis Rheum 1990;33: 364.
12. Swaak AJ, Groenwold J, Bronsveld W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 1986;45:359-366.
13. Harley JB, Alexander EL, Bias WB, et al. Anti-Ro (SS-A) and anti-La (SS-B) in patients with Sjögren's syndrome. Arthritis Rheum 1986;29: 196-206.
14. Reveille JD, Solomon DH, American College of Rheumatology Ad Hoc Committee of Immunologic Testing Guidelines. Evidenced-based guidelines for the use of Immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003;49:399-412.
15. Okano Y, Steen VD, Medsger TA Jr. Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum 1992;35:95-100.
16. Falkner D, Wilson J, Fertig N, et al. Studies of HLA-DR and DQ alleles in systemic sclerosis patients with autoantibodies to RNA polymerase and U3-RNP (fibrillarin). J Rheumatol 2000;27:1196-1202.
17. Kroot EJ, de Jong BA, van Leeuwen MA, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-1835,
18. Stone JH, Talor M, Stebbing J, et al. Test characteristics of immunofluorescence and ELISA tests in 856 consecutive patients with possible ANCA-associated conditions. Arthritis Care Res 2000;13:424-434.
19. Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis. Arthritis Rheum 1999;42:421-430.
20. Woodworth TG, Abuelo JG, Austin HA III, et al. Severe glomerulonephritis with late emergence of classic Wegener's granulomatosis: report of 4 cases and review of the literature. Medicine (Baltimore) 1987;66: 181-191.
21. Hauschild S, Scmitt WH, Csernok E, et al. ANCA in systemic vasculitides, collagen vascular diseases, rheumatic disorders and inflammatory bowel diseases. Adv Exp Med Biol 1993;336:245-251.